



FEP Medical Policy Manual

FEP 6.01.06 Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Annual Effective Policy Date: January 1, 2026

Original Policy Date: June 2012

Related Policies:

- 6.01.20 - Cardiac Applications of Positron Emission Tomography Scanning
- 6.01.26 - Oncologic Applications of Positron Emission Tomography Scanning (Genitourinary)
- 6.01.51 - Interim Positron Emission Tomography Scanning in Oncology to Detect Early Response During Treatment
- 6.01.55 - Selected Positron Emission Tomography Technologies for Evaluation of Alzheimer Disease

Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Description

Description

Positron emission tomography (PET) images biochemical and physiologic functions by measuring concentrations of radioactive chemicals that have been partially metabolized in a particular region of the body. Radiopharmaceuticals used for PET are generated in a cyclotron (nuclear generator) and then introduced into the body by intravenous injection or respiration.

Positron emission tomography (PET) scans couple positron-emitting radionuclide tracers to other molecules, such as glucose, ammonia, or water. The radionuclide tracers simultaneously emit 2 high-energy photons in opposite directions that can be simultaneously detected (referred to as *coincidence detection*) by a PET scanner, which comprises multiple stationary detectors that encircle the region of interest.

A variety of tracers are used for PET scanning, including oxygen 15, nitrogen 13, carbon 11, and fluorine 18. The radiotracer most commonly used in oncology imaging has been fluorine 18, coupled with fluorodeoxyglucose (FDG), which has a metabolism related to glucose metabolism. While FDG has traditionally been used in cancer imaging, it potentially has many other applications.

OBJECTIVE

The objective of this evidence review is to determine whether use of fluorine 18 fluorodeoxyglucose positron emission tomography improves the net health outcome in individuals with epilepsy, suspected chronic osteomyelitis, suspected large vessel vasculitis, and other noncardiac and nononcologic conditions (eg, central nervous system, pulmonary, and musculoskeletal diseases).

POLICY STATEMENT

Positron emission tomography (PET) using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) may be considered **medically necessary** in:

1. The assessment of select individuals with epileptic seizures who are candidates for surgery (see Policy Guidelines section)
2. The diagnosis of chronic osteomyelitis.

The use of FDG-PET for all other miscellaneous indications is **investigational**, including, but not limited to:

- Central nervous system diseases
 - Autoimmune disorders with central nervous system manifestations, including:
 - Behet syndrome
 - lupus erythematosus
 - Cerebrovascular diseases, including:
 - arterial occlusive disease (arteriosclerosis, atherosclerosis)
 - carotid artery disease
 - cerebral aneurysm
 - cerebrovascular malformations (arteriovenous malformation and Moya-Moya disease)
 - hemorrhage
 - infarct
 - ischemia
 - Degenerative motor neuron diseases, including:
 - amyotrophic lateral sclerosis
 - Friedreich ataxia
 - olivopontocerebellar atrophy
 - Parkinson disease
 - progressive supranuclear palsy
 - Shy-Drager syndrome
 - spinocerebellar degeneration
 - Steele-Richardson-Olszewski syndrome
 - Tourette syndrome

- Demyelinating diseases, such as multiple sclerosis
- Developmental, congenital, or inherited disorders, including:
 - adrenoleukodystrophy
 - Down syndrome
 - Huntington chorea
 - kinky-hair disease (Menkes disease)
 - Sturge-Weber syndrome (encephalofacial angiomatosis) and the phakomatoses
- Miscellaneous
 - chronic fatigue syndrome
 - sick building syndrome
 - posttraumatic stress disorder
- Nutritional or metabolic diseases and disorders, including:
 - acanthocytosis
 - hepatic encephalopathy
 - hepatolenticular degeneration
 - metachromatic leukodystrophy
 - mitochondrial disease
 - subacute necrotizing encephalomyelopathy
- Psychiatric diseases and disorders, including:
 - affective disorders
 - depression
 - obsessive-compulsive disorder
 - psychomotor disorders
 - schizophrenia
- Pyogenic infections, including:
 - aspergillosis
 - encephalitis
- Substance abuse, including the central nervous system effects of alcohol, cocaine, and heroin
- Trauma, including brain injury and carbon monoxide poisoning
- Viral infections, including:
 - HIV/AIDS
 - AIDS dementia complex
 - Creutzfeldt-Jakob disease
 - progressive multifocal leukoencephalopathy

- progressive rubella encephalopathy
 - subacute sclerosing panencephalitis
- Mycobacterium infection
- Migraine
- Anorexia nervosa
- Assessment of cerebral blood flow in newborns
 - Vegetative vs. locked-in syndrome
- Pulmonary diseases
 - Adult respiratory distress syndrome
 - Diffuse panbronchiolitis
 - Emphysema
 - Obstructive lung disease
 - Pneumonia
- Musculoskeletal diseases
 - Spondylodiscitis
 - Joint replacement follow-up
- Other
 - Giant cell arteritis
 - Vasculitis
 - Vascular prosthetic graft infection
 - Inflammatory bowel disease
 - Sarcoidosis
 - Fever of unknown origin
 - Inflammation of unknown origin.

POLICY GUIDELINES

In individuals with epileptic seizures, appropriate candidates are individuals with complex partial seizures who have failed to respond to medical therapy and have been advised to have a resection of a suspected epileptogenic focus located in a region of the brain accessible to surgery. Further, for the purposes of this review, conventional noninvasive techniques for seizure localization must have been tried with results suggesting a seizure focus but not sufficiently conclusive to permit surgery. The purpose of the positron emission tomography (PET) examination should be to avoid subjecting the individual to extended preoperative electroencephalographic recording with implanted electrodes or to help localize and minimize the number of sites for implanted electrodes to reduce the morbidity of that procedure.

This policy does not cover the use of fluorine 18 fluorodeoxyglucose positron emission tomography (FDG-PET) for diagnosis or evaluation of Alzheimer's disease or other dementias. See related evidence review 6.01.55 for Alzheimer's disease indications for FDG. This policy also does not cover oncologic or cardiovascular uses of FDG-PET. See related evidence reviews 6.01.26 and 6.01.51 for oncologic indications and 6.01.20 for cardiac indications for FDG.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

Following the U.S. Food and Drug Administration's (FDA) approval of the Penn-PET in 1989, a number of PET scan platforms have been cleared by the FDA through the 510(k) process. These systems are intended to aid in detecting, localizing, diagnosing, staging, and restaging of lesions, tumors, disease, and organ function for the evaluation of diseases, and disorders such as, but not limited to, cardiovascular disease, neurologic disorders, and cancer. The images produced by the system can aid in radiotherapy treatment planning and interventional radiology procedures.

PET radiopharmaceuticals have been evaluated and approved as drugs by the FDA for use as diagnostic imaging agents. These radiopharmaceuticals are approved for specific conditions.

In December 2009, the FDA issued guidance for Current Good Manufacturing Practices for PET drug manufacturers.¹ and, in August 2011, issued similar Current Good Manufacturing Practices guidance for small businesses compounding radiopharmaceuticals.² An additional final guidance document, issued in December 2012, required all PET drug manufacturers and compounders to operate under an approved new drug application (NDA) or abbreviated NDA, or investigational new drug application, by December 12, 2015.³

In 1994, the FDG radiotracer was originally approved by the FDA through the NDA (20-306) process. The original indication was for "the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures." Added indications in 2000 were for "Assessment of glucose metabolism to assist in the evaluation of malignancy..." and "Assessment of patients with coronary artery disease and left ventricular dysfunction...."

Multiple manufacturers have approved NDAs for FDG.⁴

See related evidence reviews 6.01.26 and 6.01.51 for oncologic indications and 6.01.20 for cardiac indications for FDG. See related evidence review 6.01.55 for Alzheimer's disease indications for FDG.

RATIONALE

Summary of Evidence

For individuals with epileptic seizures who are candidates for surgery who undergo fluorine 18 fluorodeoxyglucose positron emission tomography (FDG-PET), the evidence includes systematic reviews (following the publication of 3 TEC Assessments). Relevant outcomes are symptoms, change in disease status, functional outcomes, health status measures, quality of life (QOL), hospitalizations, medication use, and resource utilization. The TEC Assessments and Program in Evidence-based Care positron emission tomography (PET) recommendation report all concluded that FDG-PET accurately localizes the seizure focus compared with appropriate reference standards. A recent systematic review suggested it was difficult to discern the incremental value of FDG-PET in patients who have foci well localized by ictal scalp electroencephalography (EEG) and magnetic resonance imaging (MRI). The evidence on whether FDG-PET has a predictive value for a good surgical outcome is mixed. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with suspected chronic osteomyelitis who receive FDG-PET, the evidence includes meta-analyses and a prospective study published after the meta-analyses. Relevant outcomes are test accuracy and validity, other test performance measures, change in disease status, functional outcomes, QOL, and hospitalizations. One systematic review and meta-analysis from 2013 of 9 studies revealed that FDG-PET and FDG-PET plus computed tomography (CT) were useful for diagnosing suspected osteomyelitis in the foot of patients with diabetes. The results of another meta-analysis showed that FDG-PET was the most accurate mode (pooled sensitivity, 96%; pooled specificity, 91%) for diagnosing chronic osteomyelitis. The results appear to be robust across fairly diverse clinical populations, which strengthen the conclusions. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with suspected large vessel vasculitis (LVV) who receive FDG-PET, the evidence includes 7 systematic reviews of observational studies and an observational study. Relevant outcomes are test accuracy and validity, other test performance measures, symptoms, morbid events, QOL, hospitalizations, and treatment-related morbidity. Most studies included in the reviews were small and lacked controls. The reported performance characteristics were heterogeneous but reviewers were unable to determine the source of heterogeneity. Studies comparing PET with the true reference standard of biopsy or angiography are rare. There are no consensus criteria to define the presence of vascular inflammation by FDG-PET in LVV, and different parameters with visual and semiquantitative methods have been reported. Studies demonstrating changes in management based on

PET results or improvements in clinical outcomes are lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with diverse noncardiac or nononcologic conditions (eg, central nervous system, pulmonary, and musculoskeletal diseases) who receive FDG-PET, the evidence includes several systematic reviews. Relevant outcomes are overall survival, symptoms, change in disease status, functional outcomes, health status measures, QOL, hospitalizations, medication use, and resource utilization. Many studies cited in the reviews were small, retrospective, and published in the 1990s to early 2000s. Further, many studies did not directly compare a modality with another in the same patient group, nor did they correlate PET results in individual patients with improved clinical outcomes. Additional studies are needed to demonstrate that FDG-PET results can change management, and therefore improve patient outcomes to support the utility of FDG-PET. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Orthopaedic Surgeons

The American Academy of Orthopaedic Surgeons (AAOS) (2019) published evidence-based, consensus guidelines on the diagnosis and prevention of periprosthetic joint infections.⁷³ The AAOS recommendation regarding fluorine 18 fluorodeoxyglucose positron emission tomography (FDG-PET) is that there is limited strength of evidence supporting the use of FDG-PET/computed tomography (CT) to aid in the diagnosis of periprosthetic joint infections. The strength of the recommendation was rated as "limited," which was described as "Evidence from 2 or more 'Low' quality studies with consistent findings or evidence from a single 'Moderate' quality study recommending for or against the intervention or diagnostic test or the evidence is insufficient or conflicting and does not allow a recommendation for or against the intervention."

American College of Radiology

Evidence and consensus-based appropriateness criteria from the American College of Radiology are summarized in Table 1.

Table 1. Appropriateness Criteria for Miscellaneous Indications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography

Appropriateness Criteria	Last Reviewed	FDG-PET/CT Criteria
Suspected osteomyelitis, septic arthritis, or soft tissue infection (excluding spine and diabetic foot) ⁷⁴ .	2022	May be appropriate for suspected osteomyelitis; may be appropriate for suspected osteomyelitis or soft tissue infection with implanted extra-articular surgical hardware; may be appropriate for suspected septic arthritis with arthroplasty or other implanted intra-articular surgical hardware.
Movement Disorders and Neurodegenerative Diseases ⁷⁵ .	2019	May be appropriate as initial imaging for rapidly progressive dementia, suspected CJD; usually not appropriate for chorea, suspected HD; may be appropriate for initial imaging of parkinsonian syndromes; usually not appropriate for initial imaging of suspected neurodegeneration with brain iron accumulation; usually not appropriate for initial imaging of suspected motor neuron disease
Dementia and movement disorders ⁷⁶ .	2016; revised 2019	May be appropriate in patients with possible or probable AD and to differentiate suspected FTD, LBD, CJD, or vascular dementia;

		usually not appropriate in patients with suspected HD, clinical features of PD or hemochromatosis, or motoneuron disease
Imaging after total knee arthroplasty ⁷⁵ ,	2023	Usually not appropriate for routine follow-up of asymptomatic patients, in work-up for suspected periprosthetic infection, for evaluation of prosthetic loosening, or suspected periprosthetic or hardware fracture
Seizures and epilepsy ⁷⁷ ,	2014; revised 2019	Usually appropriate for surgical planning in known seizure disorder; usually not appropriate for new-onset seizure, whether unrelated to trauma or with a history of trauma; may be appropriate (disagreement) for known seizure disorder with unchanged seizure semiology; may be appropriate for known seizure disorder with change in seizure semiology or new neurologic deficit or no return to previous neurologic baseline; may be appropriate (disagreement) for known seizure disorder with a history of trauma
Crohn disease ⁷⁸ ,	2014; revised 2019	Usually not appropriate
Fever without source - child ⁷⁵ ,	2015	May be appropriate. This procedure should not be used as the initial study. Consider if extensive clinical and imaging work-up is negative.
Suspected osteomyelitis of the foot in patients with DM ⁷⁹ ,	2012; revised 2019	Usually not appropriate for initial imaging. May be appropriate for soft-tissue swelling with or without ulcer, suspected osteomyelitis or early neuropathic arthropathy changes of the foot in patients with DM, suspected osteomyelitis of the foot in patients with DM with or without neuropathic arthropathy, and additional imaging following radiographs.
Noncerebral Vasculitis ⁸⁰ ,	2021	Usually appropriate for initial imaging of suspected LVV (FDG-PET/CT). Usually not appropriate for initial imaging of suspected medium vessel vasculitis.

AD: Alzheimer disease; CJD: Creutzfeldt-Jakob disease; CT: computed tomography; DM: diabetes mellitus; FDG: fluorine 18 fluorodeoxyglucose; FTD: frontotemporal dementia; HD: Huntington disease; LBD: Lewy body disease; LVV: large vessel vasculitis; PD: Parkinson disease; PET: positron emission tomography.

Infectious Diseases Society of America

The Infectious Diseases Society of America (IDSA) and the International Working Group on the Diabetic Foot (2023) published a guideline on the treatment of diabetes-related foot infections.⁸¹ The guideline recommends magnetic resonance imaging (MRI) if the diagnosis of diabetes-related osteomyelitis needs to be confirmed, but PET is recommended as an alternative to MRI (conditional recommendation, low quality of evidence). The supporting text cites evidence regarding the high specificity of FDG-PET in this setting.

The IDSA and the Pediatric Infectious Diseases Society (2021) published an evidence-based guidelines on acute hematogenous osteomyelitis in children.⁸² Studies that validate the utility of FDG-PET for diagnosing pediatric osteomyelitis were listed as a future research need.

The IDSA (2015) published evidence-based, consensus guidelines on the diagnosis and treatment of native vertebral osteomyelitis in adults.⁸³ The guidelines stated that PET "is highly sensitive for detecting chronic osteomyelitis. A negative PET scan excludes the diagnosis of osteomyelitis, including native vertebral osteomyelitis, as the sensitivity of the test is expected to be very high in view of the high concentration of red marrow in the axial skeleton."

The IDSA (2013) published evidence-based, consensus guidelines on the diagnosis and management of prosthetic joint infections.⁸⁴ The guidelines concluded that PET should not be routinely used to diagnose prosthetic joint infection (strength of recommendation: B [based on moderate evidence]; quality of evidence: III [expert opinion and descriptive studies]). These guidelines have now been archived and replaced by an endorsement of the clinical practice guidelines on the diagnosis and prevention of periprosthetic joint infections issued by AAOS (2019) described above.

U.S. Preventive Services Task Force Recommendations

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

Not applicable.

Medicare National Coverage

The national coverage determination for FDG-PET for infection and inflammation (220.6.16) states that:

"The CMS [Centers for Medicare and Medicaid Services] is continuing its national noncoverage of FDG PET for the requested indications. Based upon our review, CMS has determined that the evidence is inadequate to conclude that FDG PET for chronic osteomyelitis, infection of hip arthroplasty, and fever of unknown origin improves health outcomes in the Medicare populations, and therefore has determined that FDG PET for chronic osteomyelitis, infection of hip arthroplasty, and fever of unknown origin is not reasonable..."⁸⁵,

REFERENCES

1. Food and Drug Administration (FDA). PET Drugs - Current Good Manufacturing Practice (CGMP). 2009; <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070306.pdf>. Accessed August 19, 2024.
2. Food and Drug Administration (FDA). PET Drugs - Current Good Manufacturing Practice (CGMP) Small Entity Compliance Guide. 2011; <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM266640.pdf>. Accessed August 20, 2024.
3. Food and Drug Administration (FDA). Guidance: Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs. 2012; <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291573.pdf>. Accessed August 21, 2024.
4. Food and Drug Administration (FDA). Positron Emission Tomography Drug Products; Safety and Effectiveness of Certain PET Drugs for Specific Indications. Federal Register. 2000;65(48):12999-13010.
5. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Positron Emission Tomography (PET) of Central Nervous System Diseases. TEC Assessments. 1992;Volume 7:Tab 3.
6. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) for the Assessment of Cerebrovascular Disease. TEC Assessments. 1996;Volume 11:Tab 35.
7. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) in the Management of Seizure Disorders. TEC Assessments. 1996;Volume 11:Tab 33.
8. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. *N Engl J Med*. Sep 08 2011; 365(10): 919-26. PMID 21899452
9. Mishra AM, Bai H, Gribizis A, et al. Neuroimaging biomarkers of epileptogenesis. *Neurosci Lett*. Jun 27 2011; 497(3): 194-204. PMID 21303682
10. Engel J, Cascino G, Ness P, et al. Outcome with respect to epileptic seizures. In: Engel J, ed. *Surgical Treatment of the Epilepsies*. New York, NY: Raven Press; 1993:609-621.
11. Courtney MR, Antonic-Baker A, Chen Z, et al. Association of Localizing 18 F-FDG-PET Hypometabolism and Outcome Following Epilepsy Surgery: Systematic Review and Meta-Analysis. *Neurology*. May 14 2024; 102(9): e209304. PMID 38626375
12. Niu N, Xing H, Wu M, et al. Performance of PET imaging for the localization of epileptogenic zone in patients with epilepsy: a meta-analysis. *Eur Radiol*. Aug 2021; 31(8): 6353-6366. PMID 33523306
13. Jones AL, Cascino GD. Evidence on Use of Neuroimaging for Surgical Treatment of Temporal Lobe Epilepsy: A Systematic Review. *JAMA Neurol*. Apr 2016; 73(4): 464-70. PMID 26926529
14. Wang X, Zhang C, Wang Y, et al. Prognostic factors for seizure outcome in patients with MRI-negative temporal lobe epilepsy: A meta-analysis and systematic review. *Seizure*. May 2016; 38: 54-62. PMID 27182689
15. Burneo JG, Poon R, Kellett S, et al. The Utility of Positron Emission Tomography in Epilepsy. *Can J Neurol Sci*. Nov 2015; 42(6): 360-71. PMID 26437611
16. Englot DJ, Wang DD, Rolston JD, et al. Rates and predictors of long-term seizure freedom after frontal lobe epilepsy surgery: a systematic review and meta-analysis. *J Neurosurg*. May 2012; 116(5): 1042-8. PMID 22304450
17. Willmann O, Wennberg R, May T, et al. The contribution of 18F-FDG PET in preoperative epilepsy surgery evaluation for patients with temporal lobe epilepsy: A meta-analysis. *Seizure*. Sep 2007; 16(6): 509-20. PMID 17532231
18. Traub-Weidinger T, Weidinger P, Grppel G, et al. Presurgical evaluation of pediatric epilepsy patients prior to hemispherotomy: the prognostic value of 18 F-FDG PET. *J Neurosurg Pediatr*. Dec 2016; 25(6): 683-688. PMID 27611898
19. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. *Clin Infect Dis*. Oct 01 2004; 39(7): 885-910. PMID 15472838
20. Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. *Clin Infect Dis*. Aug 15 2008; 47(4): 519-27. PMID 18611152
21. Jin Y, Huang K, Shao T. [18 F]Fluorodeoxyglucose ([18 F]FDG) positron emission tomography and conventional imaging modalities in the diagnosis of diabetic foot osteomyelitis: a meta-analysis. *Clin Radiol*. Sep 2024; 79(9): e1142-e1151. PMID 38880677
22. Llewellyn A, Kraft J, Holton C, et al. Imaging for detection of osteomyelitis in people with diabetic foot ulcers: A systematic review and meta-analysis. *Eur J Radiol*. Oct 2020; 131: 109215. PMID 32862106
23. Lauri C, Tamminga M, Glaudemans AWJM, et al. Detection of Osteomyelitis in the Diabetic Foot by Imaging Techniques: A Systematic Review and Meta-analysis Comparing MRI, White Blood Cell Scintigraphy, and FDG-PET. *Diabetes Care*. Aug 2017; 40(8): 1111-1120. PMID 28733376
24. Treglia G, Sadeghi R, Annunziata S, et al. Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography for the diagnosis of osteomyelitis related to diabetic foot: a systematic review and a meta-analysis. *Foot (Edinb)*. Dec 2013; 23(4): 140-8. PMID

23906976

25. Termaat MF, Raijmakers PG, Scholten HJ, et al. The accuracy of diagnostic imaging for the assessment of chronic osteomyelitis: a systematic review and meta-analysis. *J Bone Joint Surg Am.* Nov 2005; 87(11): 2464-71. PMID 16264122
26. de Winter F, van de Wiele C, Vogelaers D, et al. Fluorine-18 fluorodeoxyglucose-positron emission tomography: a highly accurate imaging modality for the diagnosis of chronic musculoskeletal infections. *J Bone Joint Surg Am.* May 2001; 83(5): 651-60. PMID 11379733
27. Schiesser M, Stumpe KD, Trentz O, et al. Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results. *Radiology.* Feb 2003; 226(2): 391-8. PMID 12563131
28. Guhlmann A, Brecht-Krauss D, Suger G, et al. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. *J Nucl Med.* Dec 1998; 39(12): 2145-52. PMID 9867159
29. Meller J, Kster G, Liersch T, et al. Chronic bacterial osteomyelitis: prospective comparison of (18)F-FDG imaging with a dual-head coincidence camera and (111)In-labelled autologous leucocyte scintigraphy. *Eur J Nucl Med Mol Imaging.* Jan 2002; 29(1): 53-60. PMID 11807607
30. Rastogi A, Bhattacharya A, Prakash M, et al. Utility of PET/CT with fluorine-18-fluorodeoxyglucose-labeled autologous leukocytes for diagnosing diabetic foot osteomyelitis in patients with Charcot's neuroarthropathy. *Nucl Med Commun.* Dec 2016; 37(12): 1253-1259. PMID 27749777
31. Gulati A, Bagga A. Large vessel vasculitis. *Pediatr Nephrol.* Jun 2010; 25(6): 1037-48. PMID 19844748
32. Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. *Arthritis Rheum.* Aug 1990; 33(8): 1129-34. PMID 1975175
33. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. *Arthritis Rheum.* Aug 1990; 33(8): 1122-8. PMID 2202311
34. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum.* Jan 2013; 65(1): 1-11. PMID 23045170
35. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis.* Mar 2009; 68(3): 318-23. PMID 18413441
36. Gonzalez-Garcia A, Fabregate M, Serralta G, et al. The utility of 18 F-FDG-PET/CT in detecting extracranial large vessel vasculitis in rheumatic polymyalgia or giant cell arteritis. A systematic review and meta-analysis. *Rev Clin Esp (Barc).* 2024; 224(7): 445-456. PMID 38852739
37. van der Geest KSM, Treglia G, Glaudemans AWJM, et al. Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging.* Nov 2021; 48(12): 3886-3902. PMID 33942141
38. Lee YH, Choi SJ, Ji JD, et al. Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis : A meta-analysis. *Z Rheumatol.* Nov 2016; 75(9): 924-931. PMID 26704559
39. Soussan M, Nicolas P, Schramm C, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. *Medicine (Baltimore).* Apr 2015; 94(14): e622. PMID 25860208
40. Puppo C, Massollo M, Paparo F, et al. Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. *Biomed Res Int.* 2014; 2014: 574248. PMID 25254211
41. Treglia G, Mattoli MV, Leccisotti L, et al. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. *Clin Rheumatol.* Oct 2011; 30(10): 1265-75. PMID 21833685
42. Besson FL, Parienti JJ, Bienvenu B, et al. Diagnostic performance of ¹⁸F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging.* Sep 2011; 38(9): 1764-72. PMID 21559981
43. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. *Ann Intern Med.* Jun 01 1994; 120(11): 919-29. PMID 7909656
44. Sammel AM, Hsiao E, Schembri G, et al. Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis: A Prospective, Double-Blind, Cross-Sectional Study. *Arthritis Rheumatol.* Aug 2019; 71(8): 1319-1328. PMID 30848549
45. Gupta A, Baradaran H, Schweitzer AD, et al. Oxygen extraction fraction and stroke risk in patients with carotid stenosis or occlusion: a systematic review and meta-analysis. *AJNR Am J Neuroradiol.* Feb 2014; 35(2): 250-5. PMID 23945227
46. Kim SJ, Pak K, Kim K, et al. Comparing the Diagnostic Accuracies of F-18 Fluorodeoxyglucose Positron Emission Tomography and Magnetic Resonance Imaging for the Detection of Spondylodiscitis: A Meta-analysis. *Spine (Phila Pa 1976).* Apr 01 2019; 44(7): E414-E422. PMID 30889146
47. Yan J, Zhang C, Niu Y, et al. The role of 18F-FDG PET/CT in infectious endocarditis: a systematic review and meta-analysis. *Int J Clin Pharmacol Ther.* May 2016; 54(5): 337-42. PMID 27008000
48. Mackie SL, Koduri G, Hill CL, et al. Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. *RMD Open.* 2015; 1(1): e000100. PMID 26535139
49. Treglia G, Taralli S, Giordano A. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. *Sarcoidosis Vasc Diffuse Lung Dis.* Oct 2011; 28(2): 87-94. PMID 22117499
50. Yin Y, Liu X, Yang X, et al. Diagnostic value of FDG-PET versus magnetic resonance imaging for detecting spondylitis: a systematic review and meta-analysis. *Spine J.* Dec 2018; 18(12): 2323-2332. PMID 30121323
51. Kosek S, Kilsved E, Danfors T, et al. Regional Metabolic Abnormalities in Autoimmune Encephalitis: A Meta-analysis of 498 Cases With Brain FDG PET. *Clin Nucl Med.* Mar 01 2025; 50(3): 208-213. PMID 39601059
52. Hao R, Yuan L, Kan Y, et al. Diagnostic performance of 18F-FDG PET/CT in patients with fever of unknown origin: a meta-analysis. *Nucl Med Commun.* Jul 2013; 34(7): 682-8. PMID 23636293
53. Besson FL, Chaumet-Riffaud P, Playe M, et al. Contribution of (18)F-FDG PET in the diagnostic assessment of fever of unknown origin (FUO): a stratification-based meta-analysis. *Eur J Nucl Med Mol Imaging.* Sep 2016; 43(10): 1887-95. PMID 27037917
54. Bharucha T, Rutherford A, Skeoch S, et al. Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. *Clin Radiol.* Sep 2017; 72(9): 764-771. PMID 28600002

55. Li Q, Tian R, Wang H, et al. Quantifying the contribution of 18 F-FDG PET to the diagnostic assessment of pediatric patients with fever of unknown origin: a systematic review and meta-analysis. *Pediatr Radiol*. Jul 2022; 52(8): 1500-1511. PMID 35348809
56. Buchrits S, McNeil R, Avni T, et al. The Contribution of 18F FDG PET-CT for the Investigation of Fever of Unknown Origin and Inflammation of Unknown Origin. *Am J Med*. Jul 2024; 137(7): 629-639. PMID 38499136
57. Kapoor RR, James C, Hussain K. Advances in the diagnosis and management of hyperinsulinemic hypoglycemia. *Nat Clin Pract Endocrinol Metab*. Feb 2009; 5(2): 101-12. PMID 19165222
58. Yang J, Hao R, Zhu X. Diagnostic role of 18F-dihydroxyphenylalanine positron emission tomography in patients with congenital hyperinsulinism: a meta-analysis. *Nucl Med Commun*. Apr 2013; 34(4): 347-53. PMID 23376859
59. Prodromou ML, Ziakas PD, Poulou LS, et al. FDG PET is a robust tool for the diagnosis of spondylodiscitis: a meta-analysis of diagnostic data. *Clin Nucl Med*. Apr 2014; 39(4): 330-5. PMID 24445277
60. Treglia G, Pascale M, Lazzeri E, et al. Diagnostic performance of 18 F-FDG PET/CT in patients with spinal infection: a systematic review and a bivariate meta-analysis. *Eur J Nucl Med Mol Imaging*. May 2020; 47(5): 1287-1301. PMID 31729539
61. Treglia G, Taralli S, Calcagni ML, et al. Is there a role for fluorine 18 fluorodeoxyglucose-positron emission tomography and positron emission tomography/computed tomography in evaluating patients with mycobacteriosis? A systematic review. *J Comput Assist Tomogr*. 2011; 35(3): 387-93. PMID 21586936
62. Yayan J, Rasche K, Franke KJ, et al. FDG-PET-CT as an early detection method for tuberculosis: a systematic review and meta-analysis. *BMC Public Health*. Jul 29 2024; 24(1): 2022. PMID 39075378
63. Caobelli F, Cobelli M, Pizzocaro C, et al. The role of neuroimaging in evaluating patients affected by Creutzfeldt-Jakob disease: a systematic review of the literature. *J Neuroimaging*. 2015; 25(1): 2-13. PMID 24593302
64. Saleem BR, Pol RA, Slart RH, et al. 18F-Fluorodeoxyglucose positron emission tomography/CT scanning in diagnosing vascular prosthetic graft infection. *Biomed Res Int*. 2014; 2014: 471971. PMID 25210712
65. Kim SJ, Lee SW, Jeong SY, et al. A systematic review and meta-analysis of 18 F-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography for detection of infected prosthetic vascular grafts. *J Vasc Surg*. Jul 2019; 70(1): 307-313. PMID 30922755
66. Mahmoodi Z, Salarzaei M, Sheikh M. Prosthetic vascular graft infection: A systematic review and meta-analysis on diagnostic accuracy of 18FDG PET/CT. *Gen Thorac Cardiovasc Surg*. Mar 2022; 70(3): 219-229. PMID 34309812
67. Jin H, Yuan L, Li C, et al. Diagnostic performance of FDG PET or PET/CT in prosthetic infection after arthroplasty: a meta-analysis. *Q J Nucl Med Mol Imaging*. Mar 2014; 58(1): 85-93. PMID 24469570
68. Kwee TC, Kwee RM, Alavi A. FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis. *Eur J Nucl Med Mol Imaging*. Nov 2008; 35(11): 2122-32. PMID 18704405
69. Zhang J, Li LF, Zhu YJ, et al. Diagnostic performance of 18F-FDG-PET versus scintigraphy in patients with inflammatory bowel disease: a meta-analysis of prospective literature. *Nucl Med Commun*. Dec 2014; 35(12): 1233-46. PMID 25192191
70. Lin CY, Chang MC, Kao CH. Comparing the Diagnostic Value of FDG PET or PET/CT With FDG PET/MR in Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. *Clin Nucl Med*. Oct 01 2024; 49(10): e492-e500. PMID 38973081
71. Niccolini F, Politis M. A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. *Eur J Nucl Med Mol Imaging*. Nov 2016; 43(12): 2244-2254. PMID 27470326
72. Pagano G, Niccolini F, Politis M. Current status of PET imaging in Huntington's disease. *Eur J Nucl Med Mol Imaging*. Jun 2016; 43(6): 1171-82. PMID 26899245
73. American Academy of Orthopaedic Surgeons (AAOS). The diagnosis and prevention of periprosthetic joint infections: evidence-based clinical practice guidelines. 2019; <https://www.aaos.org/globalassets/quality-and-practice-resources/pji/pji-clinical-practice-guideline-final-9-18-19-.pdf>. Accessed August 21, 2024.
74. American College of Radiology (ACR). ACR appropriateness criteria: Suspected Osteomyelitis, Septic Arthritis, or Soft Tissue Infection (Excluding Spine and Diabetic Foot). 2022; <https://acsearch.acr.org/docs/3094201/Narrative/>. Accessed August 20, 2024.
75. American College of Radiology (ACR). ACR appropriateness criteria: imaging after total knee arthroplasty. 2023; <https://acsearch.acr.org/docs/69430/Narrative/>. Accessed August 19, 2024.
76. Frey KA, Lodge MA, Meltzer CC, et al. ACR-ASNR Practice Parameter for Brain PET/CT Imaging Dementia. *Clin Nucl Med*. Feb 2016; 41(2): 118-25. PMID 26646994
77. American College of Radiology (ACR). ACR appropriateness criteria: seizures and epilepsy. 2019; <https://acsearch.acr.org/docs/69479/Narrative/>. Accessed August 18, 2024.
78. American College of Radiology (ACR). ACR appropriateness criteria: Crohn disease. 2019; <https://acsearch.acr.org/docs/69470/Narrative/>. Accessed August 15, 2024.
79. American College of Radiology (ACR). ACR appropriateness criteria: suspected osteomyelitis of the foot in patients with diabetes mellitus: 2019. <https://acsearch.acr.org/docs/69340/Narrative/>. Accessed August 13, 2024.
80. American College of Radiology. ACR appropriateness criteria: Noncerebral Vasculitis. 2021; <https://acsearch.acr.org/docs/3158180/Narrative/>. Accessed August 16, 2024.
81. Senneville , Albalawi Z, van Asten SA, et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). *Clin Infect Dis*. Oct 02 2023. PMID 37779457
82. Woods CR, Bradley JS, Chatterjee A, et al. Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics. *J Pediatric Infect Dis Soc*. Sep 23 2021; 10(8): 801-844. PMID 34350458
83. Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. *Clin Infect Dis*. Sep 15 2015; 61(6): e26-46. PMID 26229122

84. Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. Jan 2013; 56(1): e1-e25. PMID 23223583
85. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination for FDG PET for Infection and Inflammation (220.6.16). 2008; https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=323&ncdver=1&DocID=220.6.16&ncd_id=220.6.16&ncd_version=1&basket=ncd%25253A220%25252E6%25252E16%25253A1%25253AFDG+PET+for+Infection+and+Inflammation&bc=gAAAAgAAAAAA%3D%3D&. Accessed August 20, 2024.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
June 2012	New policy	
June 2013	Replace policy	Policy updated with literature search; Sarcoidosis added as not medically necessary indication, no other changes to policy statement.
June 2014	Replace policy	Policy update with literature review. Reference 12 added; no changes to policy statement.
June 2015	Replace policy	Policy updated with literature review; references 13-14, 19, 25, 28-29, 38-40, 42, 47-49, and 51-60 added; reference 50 updated. Vascular prosthetic graft infection, fever of unknown origin, and inflammation of unknown origin added as not medically necessary indications. Acanthocytosis and assessment of cerebral blood flow in newborns revised but no other changes to policy statements.
December 2016	Replace policy	Policy updated with literature review; references 1-15, 19-21, 32, 39, 44, and 58 added. Policy statements unchanged. Added "Fluorodeoxyglucose F 18, to the title and "FDG, to the investigational statement.
December 2017	Replace policy	Policy updated with literature review through July 25, 2017; references 27, 34, 40-41, 53, and 62 added. Policy statements unchanged. Policy title changed for consistency with terminology, "Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography.,
December 2018	Replace policy	Policy updated with literature review through July 10, 2018; references 28 and 72 added; reference 18 updated. Policy statements unchanged.
December 2019	Replace policy	Policy updated with literature review through July 8, 2019; references added. Policy statements unchanged.
December 2020	Replace policy	Policy updated with literature review through July 24, 2020; references added. Policy statements unchanged.
December 2021	Replace policy	Policy updated with literature review through August 31, 2021; references added. Alzheimer's disease information removed and added to policy 6.01.55. Policy statements regarding remaining applications unchanged.
December 2022	Replace policy	Policy updated with literature review through September 7, 2022; references added. Minor editorial refinements to policy statements; intent unchanged.
December 2023	Replace policy	Policy updated with literature review through August 24, 2023; no references added. Policy statements unchanged.
December 2024	Replace policy	Policy updated with literature review through August 19, 2024; references added. Policy statements unchanged.
December 2025	Replace policy	Policy updated with literature review through August 29, 2025; reference added. Policy statements unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.